DRUG INTERACTIONS Drug Interactions
Immunoglobulin administration can transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps and rubella. The immunizing physician should be informed of recent therapy with Vivaglobin®, Immune Globulin Subcutaneous (Human), so that appropriate precautions can be taken.
Vivaglobin® should not be mixed with other medicinal products.
|
CONTRAINDICATIONS
As with all immune globulin products, Vivaglobin®, Immune Globulin Subcutaneous (Human) is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A (IgA) deficiency (serum IgA < 0.05 g/L) who have known antibody against IgA.
|
REFERENCES
- Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972;1:1208-12.
- Waniewski I, Gardulf A, Hammarström L. Bioavailability of γ-Globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994;14(2):90-7.
- Data on file.
- Roifmann CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobuli-naemia and chronic lung disease. Lancet 1987;1(8451):1075-7.
Revised: April 2007
Part number OBAH G46 00883 (18838A)
Package Label - Principal Display Panel - 10 × 3 mL
NDC 0053-7596-03
10 × 3 mL
Viva globin ®
Immune Globulin Subcutaneous (Human)
Ten Single Use Vials
Rx only
Manufactured by: CSL Behring GmbH, 35041 Marburg, Germany
US License No. 1765
EXP.:
LOT:
CSL Behring
Package Label - Principal Display Panel - 10 mL
NDC 0053-7596-10
10 mL
Immune Globulin
Subcutaneous (Human)
Viva globin ®
One Single Use Vial
Rx only
EXP.:
LOT:
CSL Behring
|
